Metabolic risk markers in an overweight and normal weight population with oversampling of carriers of the IRS-1 972Arg-variant


      The relationship between the Gly972Arg polymorphism in the insulin receptor substrate-1 (IRS-1) gene and metabolic risk markers is not clear, possibly due to small sample sizes. Modification by body mass index (BMI) has also been suggested. Our aim was therefore to quantify the association of this 972Arg-variant with insulin, glucose and lipid levels in overweight and non-overweight subjects with oversampling of subjects with the 972Arg-variant. We first genotyped 3684 subjects selected from a large population-based cohort (n∼23,000) according to BMI (26–40 or 18–24 kg/m2). Next, we examined 600 of these subjects for fasting metabolic risk markers according to BMI-group and genotype. Subjects with the 972Arg-variant had significantly higher insulin concentrations (4.09 pmol/l or 9.6%, P=0.024) and lower triglyceride levels (0.13 mmol/l or 11%, P=0.001) compared with non-carriers when adjusted for age, sex, waist-to-hip ratio, BMI, alcohol consumption, physical activity and cigarette smoking. These associations were more pronounced in the high BMI-group, although the interactions were not statistically significant. Our large population-based sample shows that the IRS-1 Gly972Arg polymorphism relates to higher fasting insulin levels and lower triglyceride levels. The impact of this genotype and its modification by overweight may be smaller than suggested previously.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • White M.F.
        • Kahn C.R.
        The insulin signaling system.
        J. Biol. Chem. 1994; 269: 1-4
        • Sesti G.
        • Federici M.
        • Hribal M.L.
        • Lauro D.
        • Sbraccia P.
        • Lauro R.
        Defects of the insulin receptor substrate (IRS) system in human metabolic disorders.
        FASEB J. 2001; 15: 2099-2111
      1. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003 (Online First, published June 18, 2003).

        • Almind K.
        Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus.
        Lancet. 1993; 342: 828-832
        • Baroni M.G.
        • Arca M.
        • Sentinelli F.
        • et al.
        The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance.
        Diabetologia. 2001; 44: 367-372
        • Baroni M.G.
        • D’Andrea M.P.
        • Montali A.
        • et al.
        A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 2975-2980
        • Clausen J.O.
        • Hansen T.
        • Bjørbaek C.
        • et al.
        Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1.
        Lancet. 1995; 346: 397-402
        • Laakso M.
        • Malkki M.
        • Kekäläinen P.
        • Kuusisto J.
        • Deeb S.S.
        Insulin receptor substrate-1 variants in non-insulin-dependent diabetes.
        J. Clin. Invest. 1994; 94: 1141-1146
        • Ossei-Gerning N.
        • Mansfield M.W.
        • Stickland M.H.
        • Grant P.J.
        Insulin receptor substrate-1 gene polymorphism and cardiovascular risk in non-insulin dependent diabetes mellitus and patients undergoing coronary angiography.
        Clin. Lab. Haem. 1997; 19: 123-128
        • Zhang Y.
        • Stratton I.M.
        • Warren-Perry M.G.
        • Orho M.
        • Groop L.
        • Turner R.C.
        UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and beta3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations.
        Diabetologia. 1996; 39: 1505-1511
        • Verschuren W.M.M.
        • van Leer E.M.
        • Blokstra A.
        • et al.
        Cardiovascular disease risk factors in The Netherlands.
        Neth. J. Cardiol. 1993; 4: 205-210
        • van Dam R.M.
        • Boer J.M.
        • Feskens E.J.
        • Seidell J.C.
        Parental history of diabetes modifies the association between abdominal adiposity and hyperglycemia.
        Diabetes Care. 2001; 24: 1454-1459
        • Miller S.A.
        • Dykes D.D.
        • Polesky H.F.
        A simple salting out procedure for extracting DNA from human nucleated cells.
        Nucleic Acids Res. 1988; 16: 1215
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499-502
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • Naylor B.A.
        • Treacher D.F.
        • Turner R.C.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Almind K.
        • Inoue G.
        • Pedersen O.
        • Kahn R.K.
        A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling.
        J. Clin. Invest. 1996; 97: 2569-2575
        • Sigal R.J.
        • Doria A.
        • Warram J.H.
        • Krolewski A.S.
        Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus.
        J. Clin. Endocrinol. Metab. 1996; 81: 1657-1659
        • Howard B.V.
        Insulin resistance and lipid metabolism.
        Am. J. Cardiol. 1999; 84: 28J-32J
        • Phung T.L.
        • Roncone A.
        • Jensen K.L.
        • Sparks C.E.
        • Sparks J.D.
        Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum.
        J. Biol. Chem. 1997; 272: 30693-30702
        • Previs S.F.
        • Withers D.J.
        • Ren J.M.
        • White M.F.
        • Shulman G.I.
        Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo.
        J. Biol. Chem. 2000; 275: 38990-38994
        • Sparks J.D.
        • Sparks C.E.
        Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion.
        Biochim. Biophys. Acta. 1994; 1215: 9-32
        • Stumvoll M.
        • Fritsche A.
        • Volk A.
        • et al.
        The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans.
        Diabetes. 2001; 50: 882-885
        • ’t Hart L.M.
        • Nijpels G.
        • Dekker J.M.
        • Maassen J.A.
        • Heine R.J.
        • van Haeften T.W.
        Variations in insulin secretion in carriers of gene variants in IRS-1 and -2.
        Diabetes. 2002; 51: 884-887
        • Ruige J.B.
        • Dekker J.M.
        • Nijpels G.
        • et al.
        Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose.
        Diabetologia. 1999; 42: 177-180
        • Reaven G.M.
        Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis.
        Metabolism. 1987; 36: 1-8
        • Reaven G.M.
        • Chen Y.-D.I.
        • Jeppesen J.
        • Maheux P.
        • Krauss R.M.
        Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles.
        J. Clin. Invest. 1993; 92: 141-146
        • Stumvoll M.
        • Stefan N.
        • Fritsche A.
        • et al.
        Interaction effect between common polymorphisms in PPARgamma(2) (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity.
        J. Mol. Med. 2002; 80: 33-38
        • Lei H.H.
        • Coresh J.
        • Shuldiner A.R.
        • Boerwinkle E.
        • Brancati F.L.
        Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the atherosclerosis risk in communities study.
        Diabetes. 1999; 48: 1868-1872
        • ’t Hart L.M.
        • Stolk R.P.
        • Dekker J.M.
        • et al.
        Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study.
        J. Clin. Endocrinol. Metab. 1999; 84: 1002-1006